Lena Koch-Gallenkamp

Lena Koch-Gallenkamp

Auto-generated profile, based on publicly available information

Lena Koch-Gallenkamp

Division of Clinical Epidemiology and Aging Research, DKFZ, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 November 2010 in European Journal of Cancer
Verified
Journal Article
Closed access
LJLina Jansen
Lina Jansen
LKL. Koch
L. Koch
HBHermann Brenner
Hermann Brenner
VAV. Arndt
V. Arndt

30 November 2013 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
LKLena Koch
Lena Koch
HBHeike Bertram
Heike Bertram
AEAndrea Eberle
Andrea Eberle
BHBernd Holleczek
Bernd Holleczek
SSSieglinde Schmid-Höpfner
Sieglinde Schmid-Höpfner
VAVolker Arndt
Volker Arndt

29 November 2012 in Acta Oncologica
Verified
Journal Article
Open access
LKLena Koch
Lena Koch
LJLina Jansen
Lina Jansen
AHAntje Herrmann
Antje Herrmann
CSChrista Stegmaier
Christa Stegmaier
BHBernd Holleczek
Bernd Holleczek
VAVolker Arndt
Volker Arndt
Background. Breast cancer survivors may experience adverse effects of cancer and/or treatment years after completion of therapy, which can considerably decrease quality of life (QoL). Little is known about the time course of QoL in breast cancer survivors beyond the fifth year post-diagnosis, when routine follow-up care has usually terminated. We therefore explored in detail whether and to what extent restrictions in breast cancer survivors persist and whether changes or aggravations in QoL occurred over time. Material and methods. QoL was assessed 1, 3, 5, and 10 years post-diagnosis in a population-based cohort of initially 387 female breast cancer patients from Saarland (Germany), using the EORTC QLQ-C30 and QLQ-BR23. Time course of QoL over 10 years post-diagnosis was assessed for survivors and survivors’ QoL was compared cross-sectionally to the German general population after adjustment for age. Results. A total of 182 out of 238 patients alive (76.5%) responded in the 10-year, 160 patients (67.2%) participated in all follow-ups. Although breast cancer survivors and controls reported comparable general health and overall QoL, survivors reported significantly more restrictions on most functioning and symptom scales at each follow-up. Detriments in various QoL dimensions (e.g. physical and social functioning; pain, financial difficulties) aggravated from year 5 to 10. Generally, restrictions were largest for the youngest survivors. Conclusion. Relevant restrictions in QoL persist over years in breast cancer survivors and affect predominantly younger women. The aggravation of restrictions in QoL beyond the fifth year may indicate deficits in health care and psychosocial support of breast cancer patients after completion of routine follow-up care.

1 December 2016 in Health Psychology
Verified
Journal Article
Closed access
LKLena Koch-Gallenkamp
Lena Koch-Gallenkamp
HBHeike Bertram
Heike Bertram
AEAndrea Eberle
Andrea Eberle
BHBernd Holleczek
Bernd Holleczek
SSSieglinde Schmid-Höpfner
Sieglinde Schmid-Höpfner
VAVolker Arndt
Volker Arndt
Fear of recurrence (FoR) is among the most important concerns for cancer survivors. Studies on potentially influencing variables, like time since diagnosis, cancer type, and sex, have yielded heterogeneous results. Also social support has rarely been examined as an influencing factor. This study aims to increase knowledge on these factors. Analyses are based on cross-sectional data of long-term survivors of breast, colorectal, and prostate cancer (5-16 years postdiagnosis), recruited by 6 German population-based cancer registries. Six thousand fifty-seven women and men were included in the analyses. FoR was assessed using the short form of the Fear of Progression Questionnaire (FoP-Q-SF). The associations of cancer type, age, sex, time since diagnosis, and social support with moderate/high FoR were identified via multiple logistic regression analyses. The majority of long-term cancer survivors reported experiencing FoR, mostly in low intensity. Female survivors, survivors ≤54 or 55-59 years of age, 5 to 7 years postdiagnosis, with a lower education, with recurrence/metastases, or being socially isolated were at greater risk to experience moderate/high FoR. Cancer type and stage at diagnosis did not reach statistical significance. Our results indicate a potential vulnerability for women to experience FoR in moderate/high severity. Also younger and socially isolated survivors were at greater risk to suffer from moderate/high levels of FoR and should thus be monitored for high levels of FoR and be offered the support needed to manage their fears. (PsycINFO Database Record

19 February 2019 in Acta Oncologica
Verified
Journal Article
Closed access
VAVolker Arndt
Volker Arndt
LKLena Koch-Gallenkamp
Lena Koch-Gallenkamp
HBHeike Bertram
Heike Bertram
AEAndrea Eberle
Andrea Eberle
BHBernd Holleczek
Bernd Holleczek
HBHermann Brenner
Hermann Brenner
Background: With improving prognosis, the ability to return to work after cancer has become a realistic goal but only little is known regarding details such as sustainability, financial consequences, and potential determinants of return to work in long-term survivors in Germany. Methods: We studied return to work in a population-based sample of 1558 long-term cancer survivors, diagnosed in 1994–2004 with breast, colorectal or prostate cancer before age 60 (mean 50.1). Information regarding employment status and financial difficulties was obtained via mailed questionnaires from patients who were identified by six population-based cancer registries in Germany. Cumulative incidence of return to work was determined by time-to-event analysis with consideration of competing events. Chi2 tests and multiple logistic regression modeling were employed to identify potential sociodemographic and clinical determinants of return to work. Results: Within a mean period since diagnosis of 8.3 years, 63% of all working-age cancer survivors initially returned to their old job and another 7% took up a new job. Seventeen percent were granted a disability pension, 6% were early retired (not cancer-related), 4% became unemployed, and 1% left the job market for other reasons. Resumption of work occurred within the first 2 years after diagnosis in 90% of all returnees. Cancer-related reduction of working hours was reported by 17% among all returnees and 6% quit their job due to cancer within 5 years past return to work. The probability of return to work was strongly related with age at diagnosis, tumor stage, education, and occupational class but did not differ with respect to the tumor site, gender nor marital status. Conclusions: Most long-term survivors after breast, colorectal, or prostate cancer of working-age are able to return to work. However, financial problems might arise due to a reduction in working hours. An additional provision of targeted interventions for high-risk groups should be discussed.